Sökning: WFRF:(Vangsted Annette) >
Lenalidomide versus...
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
-
- Lund, Johan (författare)
- Karolinska Univ Hosp, Sweden
-
- Gruber, Astrid (författare)
- Karolinska Univ Hosp, Sweden
-
- Lauri, Birgitta (författare)
- Sunderby Hosp, Sweden
-
visa fler...
-
- Duru, Adil Doganay (författare)
- Karolinska Univ Hosp, Sweden; NSU, FL USA
-
- Blimark, Cecilie (författare)
- Sahlgrens Univ Hosp, Sweden
-
- Swedin, Agneta (författare)
- Skane Univ Hosp, Sweden
-
- Hansson, Markus (författare)
- Skane Univ Hosp, Sweden
-
- Forsberg, Karin (författare)
- Norrland Univ Hosp, Sweden
-
- Ahlberg, Lucia, 1959- (författare)
- Region Östergötland, Hematologiska kliniken US
-
- Carlsson, Conny (författare)
- Hallands Hosp, Sweden
-
- Waage, Anders (författare)
- Norwegian Univ Sci and Technol, Norway
-
- Gimsing, Peter (författare)
- Rigshosp, Denmark
-
- Vangsted, Annette Juul (författare)
- Rigshosp, Denmark; Zealand Univ, Denmark
-
- Frolund, Ulf (författare)
- Zealand Univ, Denmark
-
- Holmberg, Erik (författare)
- Inst Clin Sci, Sweden
-
- Gahrton, Gösta (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Sweden
-
- Alici, Evren (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Sweden
-
- Hardling, Mats (författare)
- Uddevalla Cent Hosp, Sweden
-
- Mellqvist, Ulf-Henrik (författare)
- Sahlgrens Univ Hosp, Sweden
-
- Nahi, Hareth (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2018-04-19
- 2018
- Engelska.
-
Ingår i: Cancer Medicine. - : WILEY. - 2045-7634. ; 7:6, s. 2256-2268
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25mg/day) or Len+Dex (25mg/day and 40mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215). In the observational study (N = 133), median time to response was 1.7 (range 0.6-9.6) months. A complete response to all treatments received in both studies was observed in 11% of patients; very good partial response and partial response rates were 31% and 38%, respectively. Corresponding response rates in the subgroup of patients who did not enter the phase 2 trial (n = 71) were 3%, 18%, and 39%, respectively. Rates of disease progression at 2years in the phase 2 trial were 47% versus 31% for Len versus Len+Dex (P = 0.14). After 36months median follow-up in surviving patients, median time to progression was not reached with Len+Dex and was 24.9months (95% confidence interval 12.5-not calculable, P amp;lt; 0.001) with Len. Three-year OS among the total observational study population was 61% (95% CI, 52-69%). The corresponding rate among patients who entered the phase 2 clinical trial was 73% (95% CI, 60-83%) and was significantly lower among those patients who achieved PR but did not proceed into the phase 2 trial (55%; P = 0.01). In the phase 2 trial, OS was 73% in both treatment arms (P = 0.70). Neutropenia and thrombocytopenia were more common with prolonged (phase 2 trial) versus short-term (observational study) Len administration but remained manageable. Prolonged treatment with Len with or without Dex provides sustained, clinically relevant responses and demonstrates an acceptable safety profile.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Clinical Trial; Lenalidomide; Multiple Myeloma
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lund, Johan
-
Gruber, Astrid
-
Lauri, Birgitta
-
Duru, Adil Dogan ...
-
Blimark, Cecilie
-
Swedin, Agneta
-
visa fler...
-
Hansson, Markus
-
Forsberg, Karin
-
Ahlberg, Lucia, ...
-
Carlsson, Conny
-
Waage, Anders
-
Gimsing, Peter
-
Vangsted, Annett ...
-
Frolund, Ulf
-
Holmberg, Erik
-
Gahrton, Gösta
-
Alici, Evren
-
Hardling, Mats
-
Mellqvist, Ulf-H ...
-
Nahi, Hareth
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Cancer Medicine
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet